Atossa Therapeutics, INC

Atossa Therapeutics announced a registered direct offering of common stock and warrants, aiming to raise approximately $4.1 million for clinical development and general corporate purposes.

Atossa Therapeutics reported Q1 2026 financial results, highlighting progress in (Z)-endoxifen development for oncology and rare diseases, including FDA designations for DMD and McCune-Albright Syndrome.

Atossa Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where directors were elected, the independent auditor was ratified, and an amendment for a potential reverse stock split was approved.

Atossa Therapeutics has entered into a settlement agreement with Intas Pharmaceuticals and Jina Pharmaceuticals to resolve ongoing patent disputes regarding its Endoxifen intellectual property.

Atossa Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting a strategic pivot towards rare disease indications for its lead drug candidate, (Z)-endoxifen, alongside ongoing breast cancer programs.

Atossa Therapeutics issued its 2026 Letter to Shareholders, detailing 2025 accomplishments in oncology and rare diseases, and outlining strategic priorities for 2026.

Atossa Therapeutics reports a net loss of $9.6 million for Q1 2026, with increased R&D expenses driven by clinical trial activities for its lead candidate, (Z)-endoxifen.

Atossa Therapeutics reported a wider net loss in Q3 2025, driven by increased research and development expenses for its lead breast cancer drug candidate, (Z)-endoxifen, while engaging with the FDA on accelerated regulatory pathways.

Atossa Therapeutics reported an increased net loss in Q2 2025 due to higher research and development expenses, while advancing its lead breast cancer drug candidate, (Z)-endoxifen, through multiple clinical trials.

Atossa Therapeutics reports a net loss of $6.7 million for Q1 2025 while advancing its (Z)-endoxifen clinical programs.

Atossa Therapeutics reported a net loss of $7.2 million for the third quarter of 2024, while highlighting positive preliminary data from its (Z)-endoxifen breast density study.

Atossa Therapeutics reported a net loss of $6.0 million for the second quarter of 2024, while continuing to advance its clinical programs for (Z)-endoxifen.

Atossa Therapeutics reports progress in its (Z)-endoxifen clinical trials for breast cancer and rare diseases, alongside continued operating losses and a recent reverse stock split.

Atossa Therapeutics' 2024 10-K filing reveals a strategic shift towards a metastatic breast cancer indication for (Z)-endoxifen, alongside ongoing Phase 2 trials and financial updates.

Atossa Therapeutics' 2023 annual report highlights ongoing clinical trials for (Z)-endoxifen and strategic investments in other healthcare opportunities, while acknowledging the need for future capital raises.

Atossa Therapeutics director Richard I. Steinhart was granted 10,000 restricted stock units as part of his compensation.

Atossa Therapeutics, Inc. reports a grant of 10,000 restricted stock units to Director Shu-Chih Chen, with vesting scheduled for May 12, 2027.

H. Lawrence Remmel, a Director at Atossa Therapeutics, Inc., was granted 10,000 Restricted Stock Units (RSUs) on May 12, 2026, which will vest one year later.

Jonathan Finn, a Director at Atossa Therapeutics, Inc., acquired 10,000 restricted stock units (RSUs) on May 12, 2026, with vesting scheduled for May 12, 2027.

Stephen J. Galli, a Director at Atossa Therapeutics, Inc., was granted 10,000 restricted stock units on May 12, 2026.

Tessa Cigler, a Director at Atossa Therapeutics, Inc., was granted 10,000 Restricted Stock Units (RSUs) on May 12, 2026, which are set to vest one year later.

Atossa Therapeutics, Inc. will hold a Special Meeting on January 20, 2026, to seek stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price rule and avoid delisting.

Atossa Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on May 8, 2025, outlining proposals for director elections, auditor ratification, executive compensation, and vote frequency.

Atossa Therapeutics is holding its annual meeting on June 27, 2024, to vote on key proposals including increasing authorized shares and amending the stock incentive plan.

The Vanguard Group reported a 4.51% beneficial ownership stake in Atossa Therapeutics Inc. as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.6% beneficial ownership stake in Atossa Therapeutics, Inc.'s common stock as of June 30, 2025.

CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a passive 4.3% beneficial ownership stake in Atossa Therapeutics, Inc. as of December 31, 2024.